首页> 外文期刊>Clinical nuclear medicine >~(18)F-FDG Uptake Changes in Liver and Mediastinum During Chemotherapy in Patients With Diffuse Large B-cell Lymphoma
【24h】

~(18)F-FDG Uptake Changes in Liver and Mediastinum During Chemotherapy in Patients With Diffuse Large B-cell Lymphoma

机译:弥漫性大B细胞淋巴瘤化疗期间〜(18)F-FDG在肝脏和纵隔中的摄取变化

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: The main objective of this study was to assess the intrasubject and intersubjects variability of ~(18)F-FDG uptake in liver (LIV) and mediastinum (MBP) among patients with diffuse large B-cell lymphoma (DLBCL), treated with different chemotherapy regimens. Patients and Methods: Fifty patients with DLBCL who underwent ~(18)F-FDG PET/CT scan at baseline, after a few cycles of therapy (interim PET) and on completion of therapy (final PET), were enrolled retrospectively. SUVmean and SUVmax values for LIVand MBP, their differences (LIV - MBP SUVmean and LIV — MBP SUVmax), and their changes were calculated, respectively. Results: Liver uptake significantly increased in the interim in comparison with baseline and final PET, respectively, whereas MBP activity remained stable during chemotherapy. The intersubject variability of ~(18)F-FDG uptake in LIV and MBP ranged from 20.2% to 25.4%. Conclusions: The variability of the LIV uptake during chemotherapy should be taken into account when this parameter is used to score the interim PET scan and to make decisions in defining response-adapted therapeutic strategies. Vice versa, the stability of MBP activity during therapy provides a more reliable benchmark for the response assessment. Finally, the intersubjects variability of both parameters should be considered when the visual evaluation of the interim PET is performed by point score models.
机译:目的:本研究的主要目的是评估在接受弥漫性大B细胞淋巴瘤(DLBCL)治疗的患者中,肝脏(LIV)和纵隔(MBP)中〜(18)F-FDG摄取的受试者体内和受试者间变异性不同的化疗方案。患者和方法:回顾性研究了50例在治疗几个周期(临时PET)和完成治疗(最终PET)后于基线进行〜(18)F-FDG PET / CT扫描的DLBCL患者。分别计算LIV和MBP的SUVmean和SUVmax值,它们的差异(LIV-MBP SUVmean和LIV-MBP SUVmax)及其变化。结果:与基线和最终PET相比,中期肝脏吸收显着增加,而化学疗法期间MBP活性保持稳定。 LIV和MBP中〜(18)F-FDG摄取的受试者间变异范围为20.2%至25.4%。结论:当使用该参数对中期PET扫描进行评分并在确定适应反应的治疗策略时做出决定时,应考虑化疗期间LIV摄取的变异性。反之亦然,治疗期间MBP活性的稳定性为反应评估提供了更可靠的基准。最后,当通过分数模型对临时PET进行视觉评估时,应考虑两个参数的受试者间差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号